Drug Type Small molecule drug |
Synonyms MB-07344, VK 2809, VK-2809 + [1] |
Target |
Mechanism THR-β agonists(Thyroid hormone receptor beta-1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H32ClO5P |
InChIKeyLGGPZDRLTDGYSQ-JADSYQMUSA-N |
CAS Registry852948-13-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis | Phase 2 | US | 15 Nov 2019 | |
Fibrosis | Phase 2 | BE | 15 Nov 2019 | |
Fibrosis | Phase 2 | FR | 15 Nov 2019 | |
Fibrosis | Phase 2 | MX | 15 Nov 2019 | |
Fibrosis | Phase 2 | PR | 15 Nov 2019 | |
Nonalcoholic Steatohepatitis | Phase 2 | US | 15 Nov 2019 | |
Nonalcoholic Steatohepatitis | Phase 2 | BE | 15 Nov 2019 | |
Nonalcoholic Steatohepatitis | Phase 2 | FR | 15 Nov 2019 | |
Nonalcoholic Steatohepatitis | Phase 2 | MX | 15 Nov 2019 | |
Nonalcoholic Steatohepatitis | Phase 2 | PR | 15 Nov 2019 |
Phase 2 | - | (1 mg QD) | wkiqupvydq(lrkuaklgrf) = jawbrlrrhf piamncmdlo (xudilvpdgj ) View more | Positive | 04 Jun 2024 | ||
(2.5 mg QD) | wkiqupvydq(lrkuaklgrf) = kwoycxhccd piamncmdlo (xudilvpdgj ) View more | ||||||
Phase 2 | - | zzqijgeuaj(vpjlvztdty) = VK2809 was well-tolerated in this study; no serious adverse events were reported in any cohort mfqvqpbwkf (nniztgheql ) | Positive | 27 Aug 2020 | |||
VK2809 10 mg QOD | |||||||
Phase 2 | - | zbqnruphyr(negukhtssl) = hjtbozchkd qpihpwutna (yqkgweqjqc ) View more | - | 11 Apr 2019 | |||
VK2809 10 mg QOD | zbqnruphyr(negukhtssl) = thfhcxvbpv qpihpwutna (yqkgweqjqc ) View more |